Curasight Past Earnings Performance
Past criteria checks 0/6
Curasight's earnings have been declining at an average annual rate of -49.7%, while the Biotechs industry saw earnings growing at 11.8% annually.
Key information
-49.7%
Earnings growth rate
-47.9%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -125.4% |
| Net Margin | n/a |
| Next Earnings Update | 02 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Curasight makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -29 | 7 | 0 |
| 31 Dec 23 | 0 | -26 | 6 | 0 |
| 30 Sep 23 | 0 | -27 | 4 | 0 |
| 30 Jun 23 | 0 | -25 | 5 | 0 |
| 31 Mar 23 | 0 | -19 | 5 | 0 |
| 31 Dec 22 | 0 | -18 | 5 | 0 |
| 30 Sep 22 | 0 | -15 | 5 | 0 |
| 30 Jun 22 | 0 | -13 | 3 | 0 |
| 31 Mar 22 | 0 | -11 | 2 | 0 |
| 31 Dec 21 | 0 | -8 | 1 | 0 |
| 30 Sep 21 | 0 | -7 | 1 | 0 |
| 30 Jun 21 | 0 | -7 | 1 | 0 |
| 31 Mar 21 | 0 | -6 | 1 | 0 |
| 31 Dec 20 | 0 | -6 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
Quality Earnings: CURAS is currently unprofitable.
Growing Profit Margin: CURAS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CURAS is unprofitable, and losses have increased over the past 5 years at a rate of 49.7% per year.
Accelerating Growth: Unable to compare CURAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CURAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: CURAS has a negative Return on Equity (-125.41%), as it is currently unprofitable.